Review



oci ly19  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    ATCC oci ly19
    Oci Ly19, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 116 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oci+ly19/YN1%2F1%2E7%2E4/pmc12712875-87-13-26
    Average 93 stars, based on 116 article reviews
    oci ly19 - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    other:

    Article Title: Mass Cytometry‐Based Approach for the Investigation of Stimulator of Interferon Genes Pathway
    Article Snippet: The human hematopoietic cell lines THP‐1 (RRID:CVCL_0006), DoHH2 (RRID:CVCL_1179), SU‐DHL‐4 (RRID:CVCL_0539), MAVER‐1 (RRID:CVCL_1831), OCI‐Ly19 (RRID:CVCL_1878), PCL12 (RRID:CVCL_2H32), HG‐3 (RRID:CVCL_Y547) and Raji (RRID:CVCL_0511) were sourced from the American Type Culture Collection (ATCC) or the German Collection of Microorganisms and Cell Cultures (DSMZ).

    Article Title: Mass Cytometry-Based Approach for the Investigation of Stimulator of Interferon Genes Pathway.
    Article Snippet: The human hematopoietic cell lines THP-1 (RRID:CVCL_0006), DoHH2 (RRID:CVCL_1179), SU-DHL-4 (RRID:CVCL_0539), MAVER-1 (RRID:CVCL_1831), OCI-Ly19 (RRID:CVCL_1878), PCL12 (RRID:CVCL_2H32), HG-3 (RRID:CVCL_Y547) and Raji (RRID:CVCL_0511) were sourced from the American Type Culture Collection (ATCC) or the German Collection of Microorganisms and Cell Cultures (DSMZ).

    Cell Culture:

    Article Title: Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.
    Article Snippet: Cell culture and CHOP treatment The normal B lymphocyte GM12878 (GM12878; Coriell, Camden, NJ, USA) was cultured in Roswell Park Memorial Institute 1640 (RPMI1640) Medium (A4192301; Gibco, Carlsbad, CA, USA) supplemented with 15% fetal bovine serum (FBS; C0227; Beyotime, Shanghai, China) and 2 mM L-glutamine (G8540; Sigma-Aldrich; St. Louis, MO, USA) [26]. .. DLBCL cell lines (OCI-LY18 (ACC 699), OCI-LY19 (ACC 528), OCI-LY1 (ACC 722), OCILY3 (ACC 761) and OCI-LY7 (ACC 688)), which were purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ; Braunschweig, Germany) and Farage (CRL-2630; American Type Culture Collection (ATCC), Manassas, VA, USA), were cultured in the RPMI1640 Medium supplemented with 10% FBS and 1% Penicillin-Streptomycin Solution (C0222; Beyotime, Shanghai, China) and 2 mM L-glutamine (G8540; Sigma-Aldrich, St. Louis, MO, USA) [27]. ..

    Article Title: Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway
    Article Snippet: The normal B lymphocyte GM12878 (GM12878; Coriell, Camden, NJ, USA) was cultured in Roswell Park Memorial Institute 1640 (RPMI-1640) Medium (A4192301; Gibco, Carlsbad, CA, USA) supplemented with 15% fetal bovine serum (FBS; C0227; Beyotime, Shanghai, China) and 2 mM L-glutamine (G8540; Sigma-Aldrich; St. Louis, MO, USA) [ ]. .. DLBCL cell lines (OCI-LY18 (ACC 699), OCI-LY19 (ACC 528), OCI-LY1 (ACC 722), OCI-LY3 (ACC 761) and OCI-LY7 (ACC 688)), which were purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ; Braunschweig, Germany) and Farage (CRL-2630; American Type Culture Collection (ATCC), Manassas, VA, USA), were cultured in the RPMI-1640 Medium supplemented with 10% FBS and 1% Penicillin-Streptomycin Solution (C0222; Beyotime, Shanghai, China) and 2 mM L-glutamine (G8540; Sigma-Aldrich, St. Louis, MO, USA) [ ]. ..



    Similar Products

    oci ly19  (ATCC)
    93
    ATCC oci ly19
    Oci Ly19, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oci+ly19/YN1%2F1%2E7%2E4/pmc12712875-87-13-26
    Average 93 stars, based on 1 article reviews
    oci ly19 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    acc 528 oci ly7 dlbcl dsmz  (DSMZ)
    95
    DSMZ acc 528 oci ly7 dlbcl dsmz
    Acc 528 Oci Ly7 Dlbcl Dsmz, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oci+ly19/OCI-LY19/us12577316-806-44-48
    Average 95 stars, based on 1 article reviews
    acc 528 oci ly7 dlbcl dsmz - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    acc 573 oci ly19 dlbcl dsmz  (DSMZ)
    94
    DSMZ acc 573 oci ly19 dlbcl dsmz
    Acc 573 Oci Ly19 Dlbcl Dsmz, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oci+ly19/SU-DHL-8/us12577316-806-39-43
    Average 94 stars, based on 1 article reviews
    acc 573 oci ly19 dlbcl dsmz - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    oci ly19  (DSMZ)
    95
    DSMZ oci ly19
    CO-005 triggers receptor capping and intracellular signaling events associated with type II anti-CD20 antibodies. (A) NU-DUL-1, (B) ULA, (C) , SU-DHL-10 and <t>(D)</t> <t>OCI-LY19</t> cells treated with 1 µg/mL CO-005, rituximab (RTX), or obinutuzumab (OBZ) for 3 or 24 hours exhibit distinct patterns of CD47 and CD20 clustering. Receptor distribution was visualized by confocal microscopy following immunofluorescence staining. Scale bar 10 µm. Cellular stress profiling was measured as following (E) Intracellular calcium flux in lymphoma cells treated with 1 µg/mL of the indicated antibodies or isotype control for 3 hours, measured by Fluo-4 AM and flow cytometry. (F) Reactive oxygen species (ROS) levels following antibody treatment (1 µg/mL, 3 hours), assessed by CellROX Green and flow cytometry. (G) Mitochondrial membrane potential (MMP) after CO-005 treatment (0.1 or 1 µg/mL) for 3 hours, determined by TMRM staining. CCCP served as a positive control for mitochondrial depolarization. (H) Effect of actin polymerization inhibition on CO-005 – induced cell death following cytochalasin pretreatment (20 µM, 15 min), measured by Annexin V and 7-AAD staining. Data represent the mean ± SD. Significance was determined by ANOVA analysis *, P < 0.01 compared to the sample treated with CO-005 or as indicated in the figure; ns indicates not significant. All experiments were performed independently three times (n = 3). MFI, mean fluorescence intensity.
    Oci Ly19, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oci+ly19/OCI-LY19/pmc12927799-30-6-15
    Average 95 stars, based on 1 article reviews
    oci ly19 - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    oci ly 19 acc 528  (DSMZ)
    95
    DSMZ oci ly 19 acc 528
    CO-005 triggers receptor capping and intracellular signaling events associated with type II anti-CD20 antibodies. (A) NU-DUL-1, (B) ULA, (C) , SU-DHL-10 and <t>(D)</t> <t>OCI-LY19</t> cells treated with 1 µg/mL CO-005, rituximab (RTX), or obinutuzumab (OBZ) for 3 or 24 hours exhibit distinct patterns of CD47 and CD20 clustering. Receptor distribution was visualized by confocal microscopy following immunofluorescence staining. Scale bar 10 µm. Cellular stress profiling was measured as following (E) Intracellular calcium flux in lymphoma cells treated with 1 µg/mL of the indicated antibodies or isotype control for 3 hours, measured by Fluo-4 AM and flow cytometry. (F) Reactive oxygen species (ROS) levels following antibody treatment (1 µg/mL, 3 hours), assessed by CellROX Green and flow cytometry. (G) Mitochondrial membrane potential (MMP) after CO-005 treatment (0.1 or 1 µg/mL) for 3 hours, determined by TMRM staining. CCCP served as a positive control for mitochondrial depolarization. (H) Effect of actin polymerization inhibition on CO-005 – induced cell death following cytochalasin pretreatment (20 µM, 15 min), measured by Annexin V and 7-AAD staining. Data represent the mean ± SD. Significance was determined by ANOVA analysis *, P < 0.01 compared to the sample treated with CO-005 or as indicated in the figure; ns indicates not significant. All experiments were performed independently three times (n = 3). MFI, mean fluorescence intensity.
    Oci Ly 19 Acc 528, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oci+ly19/OCI-LY19/bio_rxiv__64898__2026__01__23__701155-258-0-5
    Average 95 stars, based on 1 article reviews
    oci ly 19 acc 528 - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    cancer cell line oci ly19  (DSMZ)
    95
    DSMZ cancer cell line oci ly19
    CO-005 triggers receptor capping and intracellular signaling events associated with type II anti-CD20 antibodies. (A) NU-DUL-1, (B) ULA, (C) , SU-DHL-10 and <t>(D)</t> <t>OCI-LY19</t> cells treated with 1 µg/mL CO-005, rituximab (RTX), or obinutuzumab (OBZ) for 3 or 24 hours exhibit distinct patterns of CD47 and CD20 clustering. Receptor distribution was visualized by confocal microscopy following immunofluorescence staining. Scale bar 10 µm. Cellular stress profiling was measured as following (E) Intracellular calcium flux in lymphoma cells treated with 1 µg/mL of the indicated antibodies or isotype control for 3 hours, measured by Fluo-4 AM and flow cytometry. (F) Reactive oxygen species (ROS) levels following antibody treatment (1 µg/mL, 3 hours), assessed by CellROX Green and flow cytometry. (G) Mitochondrial membrane potential (MMP) after CO-005 treatment (0.1 or 1 µg/mL) for 3 hours, determined by TMRM staining. CCCP served as a positive control for mitochondrial depolarization. (H) Effect of actin polymerization inhibition on CO-005 – induced cell death following cytochalasin pretreatment (20 µM, 15 min), measured by Annexin V and 7-AAD staining. Data represent the mean ± SD. Significance was determined by ANOVA analysis *, P < 0.01 compared to the sample treated with CO-005 or as indicated in the figure; ns indicates not significant. All experiments were performed independently three times (n = 3). MFI, mean fluorescence intensity.
    Cancer Cell Line Oci Ly19, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oci+ly19/OCI-LY19/us12478689-416-1-9
    Average 95 stars, based on 1 article reviews
    cancer cell line oci ly19 - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    CO-005 triggers receptor capping and intracellular signaling events associated with type II anti-CD20 antibodies. (A) NU-DUL-1, (B) ULA, (C) , SU-DHL-10 and (D) OCI-LY19 cells treated with 1 µg/mL CO-005, rituximab (RTX), or obinutuzumab (OBZ) for 3 or 24 hours exhibit distinct patterns of CD47 and CD20 clustering. Receptor distribution was visualized by confocal microscopy following immunofluorescence staining. Scale bar 10 µm. Cellular stress profiling was measured as following (E) Intracellular calcium flux in lymphoma cells treated with 1 µg/mL of the indicated antibodies or isotype control for 3 hours, measured by Fluo-4 AM and flow cytometry. (F) Reactive oxygen species (ROS) levels following antibody treatment (1 µg/mL, 3 hours), assessed by CellROX Green and flow cytometry. (G) Mitochondrial membrane potential (MMP) after CO-005 treatment (0.1 or 1 µg/mL) for 3 hours, determined by TMRM staining. CCCP served as a positive control for mitochondrial depolarization. (H) Effect of actin polymerization inhibition on CO-005 – induced cell death following cytochalasin pretreatment (20 µM, 15 min), measured by Annexin V and 7-AAD staining. Data represent the mean ± SD. Significance was determined by ANOVA analysis *, P < 0.01 compared to the sample treated with CO-005 or as indicated in the figure; ns indicates not significant. All experiments were performed independently three times (n = 3). MFI, mean fluorescence intensity.

    Journal: ImmunoTargets and Therapy

    Article Title: The Dual Mechanism of Action of CO-005 Overcomes CD20 Resistance in Diffuse Large B-Cell Lymphoma

    doi: 10.2147/ITT.S572396

    Figure Lengend Snippet: CO-005 triggers receptor capping and intracellular signaling events associated with type II anti-CD20 antibodies. (A) NU-DUL-1, (B) ULA, (C) , SU-DHL-10 and (D) OCI-LY19 cells treated with 1 µg/mL CO-005, rituximab (RTX), or obinutuzumab (OBZ) for 3 or 24 hours exhibit distinct patterns of CD47 and CD20 clustering. Receptor distribution was visualized by confocal microscopy following immunofluorescence staining. Scale bar 10 µm. Cellular stress profiling was measured as following (E) Intracellular calcium flux in lymphoma cells treated with 1 µg/mL of the indicated antibodies or isotype control for 3 hours, measured by Fluo-4 AM and flow cytometry. (F) Reactive oxygen species (ROS) levels following antibody treatment (1 µg/mL, 3 hours), assessed by CellROX Green and flow cytometry. (G) Mitochondrial membrane potential (MMP) after CO-005 treatment (0.1 or 1 µg/mL) for 3 hours, determined by TMRM staining. CCCP served as a positive control for mitochondrial depolarization. (H) Effect of actin polymerization inhibition on CO-005 – induced cell death following cytochalasin pretreatment (20 µM, 15 min), measured by Annexin V and 7-AAD staining. Data represent the mean ± SD. Significance was determined by ANOVA analysis *, P < 0.01 compared to the sample treated with CO-005 or as indicated in the figure; ns indicates not significant. All experiments were performed independently three times (n = 3). MFI, mean fluorescence intensity.

    Article Snippet: ULA (ACC-267), Riva (ACC-585), OCI-LY18 (ACC-699), OCI-LY19 (ACC-528), and SU-DHL-10 (ACC-576) were obtained from the Leibniz Institute DSMZ–German Collection of Microorganisms and Cell Cultures (DSMZ).

    Techniques: Confocal Microscopy, Immunofluorescence, Staining, Control, Flow Cytometry, Membrane, Positive Control, Inhibition, Fluorescence

    CO-005 shifts the phagocytic balance by enhancing “eat me” and promoting macrophage- mediated clearance. ( A ) Surface Calreticulin exposure was assessed in a panel of lymphoma cell lines (NU-DUL-1, OCI-LY18, ULA, SU-DHL-6, SU-DHL-10 and Daudi) following treatment with CO-005, Rituximab (RTX), or Obinutuzumab (OBZ) for 3 hours; Doxorubicin served as a positive control. Calreticulin expression is shown relative to isotype control. (B) Phagocytosis activity of CO-005 or RTX was measured using CellTrace-labeled NU-DUL-1 and OCI-LY19 cells co-cultured with DiO-labeled RAW264.7 macrophages for 2 hours. Phagocytosed cells were quantified as %CellTrace+DiO+ by flow cytometry. Data represent the mean ± SD. Significance was determined by ANOVA analysis *, P < 0.01 compared to the sample treated with CO-005; ns indicates not significant. All experiments were performed independently three times (n = 3).

    Journal: ImmunoTargets and Therapy

    Article Title: The Dual Mechanism of Action of CO-005 Overcomes CD20 Resistance in Diffuse Large B-Cell Lymphoma

    doi: 10.2147/ITT.S572396

    Figure Lengend Snippet: CO-005 shifts the phagocytic balance by enhancing “eat me” and promoting macrophage- mediated clearance. ( A ) Surface Calreticulin exposure was assessed in a panel of lymphoma cell lines (NU-DUL-1, OCI-LY18, ULA, SU-DHL-6, SU-DHL-10 and Daudi) following treatment with CO-005, Rituximab (RTX), or Obinutuzumab (OBZ) for 3 hours; Doxorubicin served as a positive control. Calreticulin expression is shown relative to isotype control. (B) Phagocytosis activity of CO-005 or RTX was measured using CellTrace-labeled NU-DUL-1 and OCI-LY19 cells co-cultured with DiO-labeled RAW264.7 macrophages for 2 hours. Phagocytosed cells were quantified as %CellTrace+DiO+ by flow cytometry. Data represent the mean ± SD. Significance was determined by ANOVA analysis *, P < 0.01 compared to the sample treated with CO-005; ns indicates not significant. All experiments were performed independently three times (n = 3).

    Article Snippet: ULA (ACC-267), Riva (ACC-585), OCI-LY18 (ACC-699), OCI-LY19 (ACC-528), and SU-DHL-10 (ACC-576) were obtained from the Leibniz Institute DSMZ–German Collection of Microorganisms and Cell Cultures (DSMZ).

    Techniques: Positive Control, Expressing, Control, Activity Assay, Labeling, Cell Culture, Flow Cytometry

    CO-005 demonstrates potent anti-lymphoma activity across multiple xenograft models. (A) Experimental timeline for the xenograft study. Mice were inoculated subcutaneously with 1.5 × 10 6 cancer cells (red arrow, Day 0). Treatment injections (blue arrows) were administered intraperitoneally (i.p.) twice weekly, starting when tumors reached a mean volume of 150 mm 3 , for a total of three weeks. (B–D) Tumor growth (left) and survival (right) outcomes in three xenograft models: NU-DUL-1 (B) : Mice were treated with CO-005 (5 mg/kg), RTX (5 mg/kg), or isotype control (5 mg/kg), n = 6. Daudi (C) : Mice received CO-005 at 1 mg/kg or 5 mg/kg, RTX at 5 mg/kg, or a combination of CO-005 (1 mg/kg) and RTX (5 mg/kg), or isotype control (5 mg/kg), n= 5. OCI-LY19 (D) : Mice were treated with CO-005 (5 mg/kg), RTX (5 mg/kg), or isotype control (5 mg/kg), n= 6. Tumor volumes were measured biweekly by caliper and calculated as (length × width 2 )/2. Data represents the mean ± S.D, *p<0.01 (Mann–Whitney U -test), compared to the sample treated with Isotype control at the indicated day (endpoint before control animals are sacrificed); ns indicates not significant. n= animals per treatment group. Survival was monitored until the end of study, *p<0.01 (log-rank (Mantel- Cox) test.

    Journal: ImmunoTargets and Therapy

    Article Title: The Dual Mechanism of Action of CO-005 Overcomes CD20 Resistance in Diffuse Large B-Cell Lymphoma

    doi: 10.2147/ITT.S572396

    Figure Lengend Snippet: CO-005 demonstrates potent anti-lymphoma activity across multiple xenograft models. (A) Experimental timeline for the xenograft study. Mice were inoculated subcutaneously with 1.5 × 10 6 cancer cells (red arrow, Day 0). Treatment injections (blue arrows) were administered intraperitoneally (i.p.) twice weekly, starting when tumors reached a mean volume of 150 mm 3 , for a total of three weeks. (B–D) Tumor growth (left) and survival (right) outcomes in three xenograft models: NU-DUL-1 (B) : Mice were treated with CO-005 (5 mg/kg), RTX (5 mg/kg), or isotype control (5 mg/kg), n = 6. Daudi (C) : Mice received CO-005 at 1 mg/kg or 5 mg/kg, RTX at 5 mg/kg, or a combination of CO-005 (1 mg/kg) and RTX (5 mg/kg), or isotype control (5 mg/kg), n= 5. OCI-LY19 (D) : Mice were treated with CO-005 (5 mg/kg), RTX (5 mg/kg), or isotype control (5 mg/kg), n= 6. Tumor volumes were measured biweekly by caliper and calculated as (length × width 2 )/2. Data represents the mean ± S.D, *p<0.01 (Mann–Whitney U -test), compared to the sample treated with Isotype control at the indicated day (endpoint before control animals are sacrificed); ns indicates not significant. n= animals per treatment group. Survival was monitored until the end of study, *p<0.01 (log-rank (Mantel- Cox) test.

    Article Snippet: ULA (ACC-267), Riva (ACC-585), OCI-LY18 (ACC-699), OCI-LY19 (ACC-528), and SU-DHL-10 (ACC-576) were obtained from the Leibniz Institute DSMZ–German Collection of Microorganisms and Cell Cultures (DSMZ).

    Techniques: Activity Assay, Control, MANN-WHITNEY